HAL (France)
open access
Surveillance of CMV Terminase Gene Mutations in Allogeneic Hematopoietic Stem Cell Transplant Recipients Receiving Letermovir Prophylaxis
ABSTRACT Letermovir (LMV), a CMV‐specific terminase inhibitor, is recommended for cytomegalovirus (CMV) prophylaxis in CMV‐seropositive allogeneic hematopoietic stem cell transplant (alloHSCT) recipients. The association between low‐level CMV DNAemia during prophylaxis and the emergence of mutations
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Pre-engraftment Cytomegalovirus DNAemia#1126972
- Reducing Post-Letermovir CMV Infection: Efficacy of an Immune-Reconstitution-Based Scoring System to Guide Prophylaxis Duration#1292770
- Maternal Antibodies to Primary CMV Infection Link to Fetal Transmission#1306425
- A Biobehavioral Perspective on Caring for Allogeneic Hematopoietic Stem Cell Transplant Survivors with Graft-Versus-Host Disease.#406413
- CMV-CTL for the Treatment of CMV Infection After HSCT#1059166
Record · ID 1235874
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive